Alzamend Neuro Stock Price To Earning
| ALZN Stock | USD 1.26 0.03 2.33% |
Alzamend Neuro fundamentals help investors to digest information that contributes to Alzamend Neuro's financial success or failures. It also enables traders to predict the movement of Alzamend Stock. The fundamental analysis module provides a way to measure Alzamend Neuro's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alzamend Neuro stock.
Alzamend | Price To Earning |
Alzamend Neuro Company Price To Earning Analysis
Alzamend Neuro's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Alzamend Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Alzamend Neuro is extremely important. It helps to project a fair market value of Alzamend Stock properly, considering its historical fundamentals such as Price To Earning. Since Alzamend Neuro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alzamend Neuro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alzamend Neuro's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Alzamend Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, Alzamend Neuro has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Alzamend Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alzamend Neuro's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alzamend Neuro could also be used in its relative valuation, which is a method of valuing Alzamend Neuro by comparing valuation metrics of similar companies.Alzamend Neuro is currently under evaluation in price to earning category among its peers.
Alzamend Fundamentals
| Return On Equity | -44.08 | ||||
| Return On Asset | -2.14 | ||||
| Current Valuation | 5.68 M | ||||
| Shares Outstanding | 4.48 M | ||||
| Shares Owned By Insiders | 4.55 % | ||||
| Shares Owned By Institutions | 0.94 % | ||||
| Number Of Shares Shorted | 222.51 K | ||||
| Price To Book | 7.23 X | ||||
| EBITDA | (9.89 M) | ||||
| Net Income | (9.95 M) | ||||
| Cash And Equivalents | 11.53 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 300.71 K | ||||
| Current Ratio | 11.78 X | ||||
| Book Value Per Share | (1.41) X | ||||
| Cash Flow From Operations | (8.27 M) | ||||
| Short Ratio | 0.54 X | ||||
| Earnings Per Share | (142.87) X | ||||
| Target Price | 35.0 | ||||
| Beta | -0.038 | ||||
| Market Capitalization | 5.75 M | ||||
| Total Asset | 631.59 K | ||||
| Retained Earnings | (54.02 M) | ||||
| Working Capital | (2.77 M) | ||||
| Net Asset | 631.59 K |
About Alzamend Neuro Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alzamend Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alzamend Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alzamend Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alzamend Neuro
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.Moving together with Alzamend Stock
| 0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Alzamend Stock
| 0.75 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.57 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.46 | MNOV | MediciNova | PairCorr |
| 0.45 | PHVS | Pharvaris BV | PairCorr |
| 0.43 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alzamend Neuro Piotroski F Score and Alzamend Neuro Altman Z Score analysis. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.